Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia

AIMS: The aim of the phase Ib, two part SAWYER study (BO25341; NCT01292603) was to investigate the pharmacokinetics and safety of subcutaneous (s.c.) rituximab compared with intravenous (i.v.) rituximab, both in combination with fludarabine and cyclophosphamide (FC), as first line treatment for pati...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Clin Pharmacol
Prif Awduron: Assouline, Sarit, Buccheri, Valeria, Delmer, Alain, Gaidano, Gianluca, McIntyre, Christine, Brewster, Michael, Catalani, Olivier, Hourcade-Potelleret, Florence, Sayyed, Pakeeza, Badoux, Xavier
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley & Sons, Ltd 2015
Pynciau:
Clinical Trials
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4631173/
https://ncbi.nlm.nih.gov/pubmed/25900065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12662
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg